Bobbie: Laura Modi. How a Baby Formula Startup Took Market Share From Two Industry Giants

Episode Summary

Executive Summary: Laura Modi turned a personal struggle with breastfeeding into Bobby, a modern infant formula brand built to challenge a stagnant, highly regulated market dominated by Abbott and Reckitt/Mead Johnson. After early regulatory missteps, a recall, and supply-chain setbacks, Bobby won consumers by combining European-style formulation, emotional brand messaging, and relentless operational hustle.

Main Topics: From tech executive to founder (Priority: 5/5): Modi’s path from Google to Airbnb gave her startup instincts, operational rigor, and confidence to leave a stable career for an unmet market need. Motherhood, shame, and the formula gap (Priority: 5/5): Her breastfeeding difficulties exposed the stigma around formula and the lack of modern, parent-centered options in the U.S. market. Building a regulated product in a duopoly (Priority: 5/5): Infant formula is one of the most controlled food categories, requiring FDA approval, compliant facilities, and careful claims, all while competing against entrenched giants. Regulatory setback and recovery (Priority: 4/5): Bobby’s early pilot launch triggered an FDA recall, but the public response, investor support, and community backing helped the company recover and ultimately gain a key manufacturer. Brand, community, and cultural repositioning (Priority: 4/5): Bobby differentiated through emotional resonance, parent community-building, and messaging that rejected shame while emphasizing choice and support. Scaling, supply constraints, and manufacturing control (Priority: 5/5): Rapid demand exposed Bobby’s dependence on contract manufacturing, leading Modi to pursue vertical integration by acquiring a facility and brand assets. Policy and future market ambitions (Priority: 4/5): Modi argues that formula access, WIC reform, and broader acceptance of feeding choices are central to the company’s long-term mission.

Key Arguments: Formula is essential, but U.S. consumers were offered limited choice in a market ignored for decades. Breast milk is ideal, but not all mothers can exclusively breastfeed; formula should not carry stigma. The U.S. formula market lagged Europe in standards and ingredient choices, especially around DHA and updated nutrition rules. Breaking into infant formula requires more than a good recipe; manufacturing, regulatory strategy, and timing are decisive. Bobby’s early FDA recall was a painful but necessary lesson in compliance and legitimacy. Community trust and emotionally resonant branding were as important as product formulation. Owning manufacturing became necessary once growth exposed Bobby’s dependence on scarce contract capacity. Policy change matters because programs like WIC shape access for millions of families.

Data Points: U.S. baby formula market size: $6 billion - Size of the infant formula market Modi entered in the U.S. Market share of Bobby: about 4% - Bobby’s share of the U.S. baby formula market after just over five years Expected first-year sales: $4 million - Modi’s initial forecast for Bobby’s first year Actual first-year sales: $16 million - Bobby’s sales in 2021 after launch Actual second-year sales: $84 million - Bobby’s sales in 2022 amid formula shortage demand First capital raised: $2.5 million - Seed/early funding secured after 64 investor pitches Additional funding after recall: $4 million - Capital raised following the FDA shutdown and recall Personal startup budget: about $200,000 - Money Modi ultimately spent before institutional funding, drawn from savings and other sources Investor meetings: 64 - Number of investor pitches before the first successful round Yeses from investors: 4 - Positive responses from the 64 pitches Lead time to produce formula: 5 to 6 months - Time needed to manufacture and test infant formula before it could reach market Duration of supply setback: almost 7 months - Period Bobby went out of stock in 2024 First customers: 93 - Initial direct-to-consumer families served in San Francisco Standards gap: 1980s - Last time U.S. infant formula nutritional standards were updated European review cycle: every 4 to 5 years - How often European standards were updated

Pivotal Quotes: "what I was doing was terrible: that women should be breastfeeding" — Laura Modi: Describing an investor’s dismissive reaction to her infant formula startup "it looks like a duck, it quacks like a duck. This is infant formula" — FDA inspector: The FDA’s assessment during Bobby’s early pilot launch and recall "No one should be embarrassed about how they're feeding their baby" — Laura Modi: Modi’s long-term cultural goal for Bobby and the broader feeding conversation

Implications: Bobby shows that regulated consumer categories can still be disrupted if founders pair product quality with compliance, branding, and supply-chain control. It also highlights growing pressure to reform formula access, standards, and parent stigma.